Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience

Recent developments in the field of targeted therapy have led to the discovery of a new drug, plerixafor, that is a specific inhibitor of the CXCR4 receptor. Plerixafor acts in concert with granulocyte colony-stimulating factor (G-CSF) to increase the number of stem cells circulating in the peripher...

Descripción completa

Detalles Bibliográficos
Autores principales: Basak, Grzegorz Wladyslaw, Knopinska-Posluszny, Wanda, Matuszak, Magdalena, Kisiel, Elzbieta, Hawrylecka, Dorota, Szmigielska-Kaplon, Anna, Urbaniak-Kujda, Donata, Dybko, Jaroslaw, Zielinska, Patrycja, Dabrowska-Iwanicka, Anna, Werkun, Joanna, Rzepecki, Piotr, Wroblewska, Wiktoria, Wiktor-Jedrzejczak, Wieslaw
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070880/
https://www.ncbi.nlm.nih.gov/pubmed/20938660
http://dx.doi.org/10.1007/s00277-010-1098-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070880/
https://www.ncbi.nlm.nih.gov/pubmed/20938660
http://dx.doi.org/10.1007/s00277-010-1098-7

Ejemplares similares